Genopathy
Gene-Disorder Association · Article
Gene
FANCA
FA Complementation Group A
Manually curatedApproved treatment annotated
Association Review

In brief

The association between FANCA (FA Complementation Group A) and Ovarian Cancer is well established and manually curated, with its 2 contributing sources — 1 of them expert-curated — recording likely-pathogenic variants.

Sources 2
Clinical variants 10
Symptoms 8
Compounds 2
Trials 200of 3,692 via FANCA compounds
Publications 0
01
At a glance

Association overview

A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.

Request access
02
Provenance

Evidence and sources

2 sources

Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.

Request access
03
FANCA

The gene

1 source summary

A gene summary alongside the source descriptions it was distilled from.

Request access
04
Ovarian Cancer

The disorder

19 database identifiers

The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).

Request access
05
Phenotype

Clinical features

3 clinical features

The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.

Request access
06
ClinVar and variant evidence

Genetic basis

10 clinical variants

ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.

Request access
07
Population genetics

GWAS signals

1 GWAS phenotype

Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.

Request access
08
Interventions

Therapeutics

2 compounds & drugs

Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.

Request access
09
Human studies

Clinical trials

3,692 clinical trials

Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.

Request access
10
Provenance

References & sources

9 references

Every source and publication cited across this dossier, as one numbered reference list.

Request access